ClinVar Miner

Submissions for variant NM_033629.6(TREX1):c.58dup (p.Glu20fs)

dbSNP: rs78300695
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000114330 SCV000484428 pathogenic Aicardi-Goutieres syndrome 1 2015-05-05 criteria provided, single submitter clinical testing This heterozygous duplication variant is predicted to create a substitution of a glutamic acid to a glycine at position 75 and cause a frameshift and premature truncation 82 amino acids downstream, NP_057465.1(TREX1): p.(Glu75Glyfs*82). This change is predicted to be disease-causing by in-silico models and is novel. It was identified in a patient with clinical features of AGS, and a second truncating mutation in trans.
Labcorp Genetics (formerly Invitae), Labcorp RCV001384732 SCV001584366 pathogenic Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 2023-12-30 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu20Glyfs*82) in the TREX1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 295 amino acid(s) of the TREX1 protein. This variant is present in population databases (rs748398051, gnomAD 0.1%). This premature translational stop signal has been observed in individual(s) with autosomal recessive Aicardi-Goutieres syndrome and neurological features (PMID: 16845398, 25604658). This variant is also known as 58_59insG (E20fs). ClinVar contains an entry for this variant (Variation ID: 126390). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the TREX1 protein in which other variant(s) (p.Arg164*) have been determined to be pathogenic (PMID: 16845398, 25604658). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego RCV001731376 SCV001984797 pathogenic TREX1-related disorder 2020-10-28 criteria provided, single submitter clinical testing This frameshift variant is found in the only exon of TREX1, and frameshift variants located downstream of this variant have been reported as disease-causing variants in the Human Gene Mutation Database (PMID: 24183309, 20301648). This variant has been previously reported as a compound heterozygous and a homozygous change in patients with Aicardi-Goutieres syndrome (PMID: 16845398, 26182405, 28832562, 29453417). It is present in the heterozygous state in the gnomAD population database at a frequency of .013% (32/251392) and thus is presumed to be rare. Based on the available evidence, the c.28dup (p.Glu10GlyfsTer82) variant is classified as Pathogenic.
Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences RCV000114330 SCV001994861 pathogenic Aicardi-Goutieres syndrome 1 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV003137626 SCV003823657 pathogenic not provided 2023-12-25 criteria provided, single submitter clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV000114330 SCV003922196 pathogenic Aicardi-Goutieres syndrome 1 2023-05-02 criteria provided, single submitter curation The homozygous p.Glu20GlyfsTer82 variant in TREX1 was identified by our study in one individual with Aicardi Goutieres syndrome. The p.Glu20GlyfsTer82 variant in TREX1 has been previously reported in 12 unrelated individuals with Aicardi Goutieres syndrome 1 (PMID: 26938784, PMID: 33235754, PMID: 25604658, PMID: 16845398) but has been identified in 0.1% (32/30616) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs770193197). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. Of these 12 previously reported unrelated individuals (PMID: 26938784, PMID: 33235754, PMID: 25604658, PMID: 16845398), 7 were homozygotes (PMID: 16845398, PMID: 25604658), 1 was a compound heterozygote who carried a likely pathogenic variant in trans (PMID: 26938784, ClinVar ID: 369666), and 2 were compound heterozygotes who carried pathogenic or likely pathogenic variants in unknown phase (PMID: 33235754, ClinVar Variation ID: 126384, 126392), which increases the likelihood that the p.Glu20GlyfsTer82 variant is pathogenic. This variant has also been reported in ClinVar (Variation ID: 126390) and has been interpreted as pathogenic by Invitae, Rady Children's Institute for Genomic Medicine, Murdoch Childrens Research Institute Victorian Clinical Genetics Services, GeneReviews, and Sanjay Gandhi Post Graduate Institute of Medical Sciences Department of Medical Genetics. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 20 and leads to a premature termination codon 82 amino acids downstream. This termination codon occurs within the last exon and is more likely to escape nonsense mediated decay (NMD) and result in a truncated protein. Loss of function of the TREX1 gene is an established disease mechanism in autosomal recessive Aicardi Goutieres syndrome 1. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Aicardi Goutieres syndrome 1. ACMG/AMP Criteria applied: PVS1_Strong, PM3_Strong (Richards 2015).
Lifecell International Pvt. Ltd RCV000114330 SCV003924379 pathogenic Aicardi-Goutieres syndrome 1 criteria provided, single submitter clinical testing A Homozygote Frameshift variant c.26_27insG in Exon 2 of the TREX1 gene that results in the amino acid substitution p.Glu10fs*82 was identified. The observed variant has a minor allele frequency of 0.00013% in gnomAD exomes and novel in gnomAD genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score. Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic [Variation ID: 126390]. The observed variant has been previously reported as a compound heterozygous and a homozygous mutation in patients with Aicardi-Goutieres syndrome (Dillon OJ, et.al., 2018). For these reasons, this variant has been classified as Pathogenic.
PreventionGenetics, part of Exact Sciences RCV001731376 SCV004725028 pathogenic TREX1-related disorder 2023-12-24 criteria provided, single submitter clinical testing The TREX1 c.58dupG variant is predicted to result in a frameshift and premature protein termination (p.Glu20Glyfs*82). This variant (aka c.223dup, p.Glu75Glyfs*82) has been reported in the homozygous or compound heterozygous states in multiple individuals with Aicardi-Goutières syndrome (Crow et al. 2006. PubMed ID: 16845398; Crow et al. 2015. PubMed ID: 25604658. Table S1; Lim et al. 2015. PubMed ID: 26182405. Supplementary file 1; Dillon et al. 2018. PubMed ID: 29453417. Table S1). This variant is reported in 0.10% of alleles in individuals of South Asian descent in gnomAD. Frameshift variants in TREX1 are expected to be pathogenic. This variant is interpreted as pathogenic.
GeneReviews RCV000114330 SCV000147897 pathogenic Aicardi-Goutieres syndrome 1 2014-03-13 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.